It’s nearly a year and a half since Johnson & Johnson split off its consumer-health arm to focus on pharmaceuticals and medical technology. Johnson & Johnson has wasted no time expanding its ...

Speaker Mike Johnson is replacing Rep. Mike Turner as chairman of the House Intelligence Committee after a debacle that started with a warning about Russian space nuclear technology last year ...

For the third year in a row, other NFL teams are interested in Lions offensive coordinator Ben Johnson to potentially fill a vacant head coaching position. Johnson has been a hot commodity ever ...

One prospect you haven't heard as much about lately is second baseman Termarr Johnson, who has seen his prospect star fade recently. According to MLB Pipeline, Johnson was the No. 26 prospect in ...

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...

Bryan Johnson has dropped the medicine he had been taking for last five years. Bryan Johnson, the 47-year-old tech entrepreneur who has spent millions on his quest to reverse his biological age ...

Anti-aging advocate Bryan Johnson, who gulps down 54 pills for breakfast, recently discovered a wrinkle in his meticulous approach to dodging death. Every two weeks, the 47-year-old tech ...

Diontae Johnson's 2024 odyssey has reached another twist. The Texans waived Johnson on Tuesday, the team announced. "With Diontae, unfortunately it didn't work out and we're on to the Chiefs ...

The Diontae Johnson experiment is over in Houston. The Texans announced Tuesday they had waived the former Pro Bowl wideout ahead of their divisional-round matchup vs. the Kansas City Chiefs.

NEW BRUNSWICK, N.J. and BEDMINSTER, N.J., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Johnson & Johnson (NYSE: JNJ) and Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced ...

(RTTNews) - Johnson & Johnson (JNJ) and Intra-Cellular Therapies, Inc. (ITCI) announced Monday that they have entered into a definitive agreement under which Johnson & Johnson will acquire all ...

Johnson & Johnson has opened the J.P. Morgan Healthcare Conference with a bang, buying out Intra-Cellular Therapies for $14.6 billion. At $132 per share, J&J paid a 39% premium on Friday’s ...